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Abstract
Many new decision aids are developed while aspects of existing decision aids could also be useful, leading 
to a sub-optimal use of resources. To support treatment decision-making in prostate cancer patients, a 
pre-existing evidence-based Canadian decision aid was adjusted to Dutch clinical setting. After analyses 
of the original decision aid and routines in Dutch prostate cancer care, adjustments to the decision aid 
structure and content were made. Subsequent usability testing (N = 11) resulted in 212 comments. Care 
providers mainly provided feedback on medical content, and patients commented most on usability and 
summary layout. All participants reported that the decision aid was comprehensible and well-structured and 
would recommend decision aid use. After usability testing, final adjustments to the decision aid were made. 
The presented methods could be useful for cultural adaptation of pre-existing tools into other languages 
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and settings, ensuring optimal usage of previous scientific and practical efforts and allowing for a global, 
incremental decision aid development process.
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Background
Decision aids (DAs) are tools designed to support the process of shared decision-making (SDM) 
between patients and their clinician.1,2 DAs can have multiple formats (e.g. leaflets, website), but 
should at least create choice awareness, offer balanced information and stimulate patients to con-
sider their preferences.3 In general, DAs are associated with increased knowledge, more accurate 
risk perceptions and more conservative treatment preferences.4 The International Patient Decision 
Aids Standards (IPDAS) provide DA developers consensus-based criteria to ensure DA quality.5 
To help DA developers, a checklist is available that includes nine categories to which the DA 
should comply (e.g. Provide sufficient information about the decision and using high-quality 
evidence).6
A particularly fruitful area for the application of DAs is prostate cancer (Pca) care. Pca is the 
most common cancer in men in the Western world.7 Pca treatment guidelines do not indicate a 
single superior treatment option but recommend a shared treatment decision between clinician and 
patient.8 However, selecting the best suiting treatment from the available alternatives can be a 
burden for many patients. The process involves careful consideration of the risks and benefits of 
multiple treatments and weighing this against preferences and personal characteristics. Decision-
making is further complicated by sub-optimal information provision and a possible misinterpreta-
tion of patient preferences by clinicians, which emphasizes the potential benefits from DAs in Pca 
care.9–11
Recent reviews of Pca DA trials concluded that current Pca DAs provide good quality infor-
mation and help to increase patients’ knowledge.12,13 Despite improved information provision, 
current DAs do not guarantee that SDM takes place. Moreover, content, format and presenta-
tion of Pca information within DAs varied substantially, with many failing to comply to all 
components of the IPDAS criteria.12,13 The most identified shortcomings consisted of not 
including physicians and patients during DA development, a lack of balanced information on 
all options and the absence of explanation about the evidence used in the DA.13 Rather than 
resolving these issues with current tools, often new tools are developed elsewhere. This further 
increases the variety and number of available tools, though routine use in clinical practice of 
these tools remains limited.14
As many care providers articulated the need for a suitable Dutch DA, we built an interactive 
website based on an existing evidence-based online Canadian DA, developed by Feldman-
Stewart and colleagues15–19 as a starting point for further development in the Dutch situation. 
This article describes the development process of the DA and usability evaluation in Dutch 
clinical setting.
Methods
The DA development process and usability testing among relevant user groups consisted of six 
stages and was based on the model described by Kushniruk.20 This model describes the typical 
system development starting from initial analysis, prototype development and evaluation, but 
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allows for more input and changes in every development step compared to more traditional 
methodologies that have a fixed order of steps. Each stage was worked on by a multidiscipli-
nary development team of urologists, psychologists and engineers (N = 6). This section will 
discuss the stages in the development process, and the final DA as outcome is described in the 
“Results” section.
Stage 1: translating the pre-existing DA
The background and validation of the existing Canadian DA has been described thoroughly, with 
particular focus on the information needs of Pca patients when making a treatment decision.15–19 
The validity of all topics covered by the original DA for Dutch patients was also confirmed by an 
earlier cross-country comparison (including The Netherlands) of information needs in Pca 
patients.21 Therefore, all content from the original DA was translated from English to Dutch.
Stage 2: evaluating Dutch clinical routine
To investigate typical conversation flow in consultations about Pca treatment decision-making, 
all non-clinicians within the development team observed consultations between patients and 
urologist in the outpatient clinic of the initiating hospital. In addition to these observations of 
actual consultations, role playing was used to emphasize the steps clinicians usually take in 
treatment decision-making consultations with a patient. Role playing was performed by the two 
clinicians involved in the development team, with one of them simulating the patient role. 
Other members from the development team observed with special focus on the structure of the 
simulated consultations.
Stage 3: DA re-design
Following the observations from stage 2, the original DA was re-designed to fit with typical con-
versation flow as observed in stage 2. Moreover, the translated textual content from stage 1 was 
further adjusted to comply with Dutch and European treatment guidelines. All content was re-
written according to standards for creating web-based text to ensure readability and comprehensi-
bility for all literacy groups (e.g. maximum of 10–15 words per sentence and 5–10 sentences per 
paragraph, clear headings and active phrasing).22,23 Readability and comprehensibility was later 
assessed by an expert in medical communication from the initiating hospital, who was not involved 
in the further development of the DA.
Stage 4: development of explicit value clarification exercises
For use in patient DAs, IPDAS defines that value clarification exercises (VCEs) should “help 
patients to clarify and communicate the personal value of options,” in order to ultimately increase 
congruence between personal preferences and the selected treatment option.24 However, without 
clear design guidelines for VCEs, a variety of exercises have been developed with little knowledge 
about which features actually work best.25–28 A recent review suggests that VCEs should at least 
include trade-offs between option attributes in order to encourage value congruent decision-mak-
ing.29 Therefore, from all topics covered in the DA, those topics that differentiate between treat-
ments were selected to create explicit VCEs. To present these topics as a trade-off, statements were 
presented in such way that an answer to each statement was related to a (type of) treatment. VCEs 
were developed within the development team and reviewed from the perspective of the disciplines 
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present in the development team (urology, psychology, engineering design). After consensus by the 
development team, VCEs were added to the DA. The content and phrasing of the VCEs were fur-
ther evaluated during usability testing.
Stage 5: usability testing
After completion of the first version of the adjusted DA, a usability test was conducted among 
patients and care providers (N = 11).
Setting and participants. Participants for usability testing were recruited in the initiating hospital 
in the southern region of The Netherlands, by the clinicians from the development team. Four 
urologists (not involved in the DA development), two oncology nurses, one radiation oncolo-
gist and four Pca patients with recent experience in Pca treatment decision-making agreed to 
participate in usability testing. All patients were between 55 and 65 years of age and within 
6 months of Pca diagnosis. Patients with experience in the decision situation were selected 
because they were expected to be better able to imagine the situation of just having received a 
Pca diagnosis.30 IPDAS therefore also requires that DA testing is performed by experienced 
patients.6 Care providers were included in this usability test to ensure the DA content and usa-
bility would match their usual routines and their experiences with patients facing Pca treatment 
decisions. Also, care providers’ review during development is required by IPDAS.6 All care 
providers included in usability testing were affiliated to the initiating hospital, but not involved 
in any other stage of DA development. Care providers ages ranged from 35 to 60 years and all 
had a minimum of 5 years of experience in their current position. All participants were instructed 
to use the DA from the perspective of a patient diagnosed with low-risk Pca and eligible for all 
four treatments covered in the DA (active surveillance, surgery, brachytherapy and external 
beam radiotherapy). No specific further usage instructions were given in order to let partici-
pants use the DA as naturalistically as possible.
Participants were asked to think aloud when navigating through the DA and to mention every 
remark or difficulty they encountered during DA usage. This procedure is commonly used to 
investigate human–computer interactions and has been applied before for DA usability testing as 
well.31 The usability test was run in two simultaneous sessions in the outpatient clinic of the 
initiating hospital, with two observers from the development team present in each session. The 
observers monitored whether the participants’ verbalization matched their DA usage (e.g. saying 
navigation was easily accompanied by clicking on the correct buttons). As the DA only consists 
of a limited number of steps, if any action was not verbalized by the participant, a clarifying 
question was asked to the participant. During DA usage, participants did not receive further 
feedback or other instructions from the observers. Each participant was given 30 min to use the 
DA followed by a 15-min semi-structured interview. The goal of the interview was to reflect on 
DA usage in addition to the comments made while using the DA. Interviews are commonly 
added to think-aloud procedures to ensure that the most important aspects have been covered 
during the usability test and to reduce the risk of bias in the interpretation of participants’ ver-
balizations.32 The interview covered five questions asked to all participants: (1) “What were 
your expectations upfront?” (2) “What is your first impression of the DA?” (3) “Was the infor-
mation understandable and useful?” (4) “What were positive aspects?” and (5) “What can be 
improved?” Only patients were then asked the following: (1) “Would you recommend this to 
other patients?” and (2) “What feeling does the DA gave you?” Care providers were asked 
whether they would offer this DA to patients. Participants were then thanked for their participa-
tion and received a bottle of wine as token of appreciation for participating.
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Measures and analysis. As a first step, all notes from all sessions and observers were combined and 
labeled as either general comments about the DA or related to a specific section of the DA. All 
comments were then further categorized to Usability, Layout, Language, Content, Amount, Val-
ues Clarification or DA Summary. Next, the accuracy and urgency of all comments were dis-
cussed by the development team to determine the implications for DA adjustments. If consensus 
was reached on the need for changes, this led to final adjustments in the DA.
Stage 6: final adjustments
Usability testing resulted in final adjustments to the DA (described in “Results” section). Finally, 
the DA was evaluated for compliance with the IPDAS criteria.6
Results
DA
Stage 1 resulted in a plain text translation of the original Canadian DA on a prototype website. 
From the observations of conversation flow in clinical practice (stage 2), it was learned that fol-
lowing diagnosis clinicians often do not go into detail about all treatment options immediately. If 
eligible for active surveillance, treatment options are first presented as a consideration between 
active surveillance and curative treatment, before curative treatment options are discussed in 
more detail. In order to tailor the DA to this typical conversation flow during consultation, the DA 
was designed into four steps. Table 1 provides an overview of all topics covered in DA steps 1–3.
DA step 1: general Pca information. This introducing step provides background information about 
Pca in general. The anatomy of the prostate and the commonly used terms prostate-specific antigen 
(PSA) and Gleason are explained.
DA step 2: active surveillance versus curative treatment. The pros and cons of not treating immediately 
are compared to (immediate) curative treatment (Table 1). Specific treatment characteristics are 
not yet discussed in detail. Step 2 ends with VCEs on topics that require trade-offs between cura-
tive treatment and AS (Table 2).
DA step 3: surgery versus radiotherapy. If patients are still undecided or have a preference for cura-
tive treatment following step 2, they continue to step 3. This step explains the difference between 
surgery and radiotherapy in more detail (Table 1). An example page from this step is provided in 
Figure 1. Patients who already prefer AS after step 2 are allowed to skip this step. Step 3 ends with 
VCEs on topics that differentiate between surgery and radiotherapy (Table 2). If patients already 
indicated a preference for AS in step 2, continuing with step 3 is optional.
DA step 4: summary. An overview of how many topics have been read and the responses to VCEs 
are provided in a printable summary at the end of the DA (Figure 2). This summary can be taken 
by the patient to the next consultation with the clinician in order to further facilitate SDM. Alterna-
tively, the summary can be accessed online during consultation.
Usability testing
Usability testing resulted in 212 usability and content comments. Care providers mainly reported 
feedback on the specific radiotherapy-related content, a need for more descriptive notes to 
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accompany the illustrations and risk representations. Patients mainly reported usability remarks 
and comments about the DA summary section. All participants reported that the writing style was 
comprehensible and that the DA structure and navigation were clear. A summary of the results from 
the think-aloud procedure and interview results are presented in Table 3. In addition to the usability 
items, all care providers (100%) indicated that they would offer the DA to patients, and all patients 
(100%) indicated that they would recommend the DA to other patients. After discussion of the 
results in the development team, three main adjustments to the final DA were made: (1) accompa-
nying legends were added, (2) radiotherapy content was adjusted and (3) the DA summary section 
was simplified. The final version of the DA complied to all IPDAS criteria6 (Table 4).
Discussion
This article describes the development of a Dutch Pca treatment DA, based on an evidence-based 
Canadian Pca treatment DA and the subsequent usability testing among relevant user groups. 
Results of usability testing show that the DA was evaluated positively by patients and care provid-
ers and both groups would recommend use of the DA in clinical practice. The described develop-
ment method could be useful for adaptation of other pre-existing and validated tools to different 
cultural or local circumstances.
Development of DAs is an effortful process and usually involves multiple rounds of assessing 
needs, required content and preferred structure among patients and care providers.33 An important 
benefit of the proposed model of adapting a pre-existing tool is that these steps are already taken. 
Table 1. Content covered in Dutch DA.
Step 1: Introduction
 What is prostate cancer?
 What do PSA and Gleason mean?
 How does prostate cancer progresses?
 What is the effect on my life expectancy?
Step 2: Curative treatment versus active surveillance
 What is active surveillance?
 What treatments are there?
 What are the advantages?
 What are the disadvantages?
 What are the risks?
 What is the chance of a rising PSA?
 What is the risk of dying from prostate cancer?
Step 3: Surgery versus radiotherapy
 What is the procedure for surgery?
 What is the procedure for radiation therapy?
 What are the advantages?
 What are the disadvantages?
 What is the risk for erectile dysfunction?
 What is the risk for bladder dysfunction?
 What is the risk for bowel problems?
 How do I know if treatment was successful?
 What if the cancer progresses or treatment is not successful?
PSA: prostate-specific antigen; DA: decision aid.
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For the current DA, the content was previously validated,15–19 and a cross-cultural comparison also 
confirmed importance of the included topics to Dutch patients.21
The availability of validated content made it possible to focus more on the fit between DA struc-
ture and typical conversation flow in routine clinical practice. Many DAs have been developed for 
use independent from the consultation,34 which may have led to a suboptimal fit between conversa-
tion flow during consultation and DA structure. A known barrier related to limited DA uptake in 
clinical practice is that clinicians often find DAs impractical to use or that other consultation-spe-
cific factors limit structural DA implementation.35 Therefore, additional observations of clinical 
consultations and role playing took place and identified a two-step approach in discussing Pca 
treatment alternatives with patients. Instead of offering four alternative treatments simultaneously, 
a first step contains choosing between active surveillance and curative treatment and a second step 
discusses curative treatments in more detail. By also transferring this two-step approach from con-
sultation into the DA, it is expected that patients experience a more natural fit between consultation 
and DA usage. Moreover, the DA provides direct support to the clinician’s explanation.
To further improve facilitation of SDM, we added two features to the DA. First, VCEs were 
developed and added to the DA. Second, the DA ends with a printable summary of preferences and 
responses to the VCEs that the patient can bring to his clinician for discussion. The summary pro-
vides the clinician with insight on what matters most to the patient and to what extent the patient 
has formed a preference or is still undecided. The following consultation and additional decisional 
support (e.g. consultations with nurses, radiotherapists) can then be adjusted accordingly. A cluster 
Table 2. DA value clarification exercises (VCEs).
Step 2: Curative treatment versus active surveillance
Topic Reasons for active surveillance Reasons for treatment
Acceptance of deferring 
treatment
I am confident enough that I 
will be treated on time
I do not want to postpone 
treatment because I do not 
want to be too late
Avoiding possible 
unnecessary treatment
If treatment might be 
unnecessary, I would rather 
wait
I prefer treatment even if it 
might be unnecessary
Acceptance of 
treatment side-effects
I find possible treatment side 
effects like erectile and urinary 
dysfunctions difficult to accept
I find the possible 
treatment side effects 
acceptable
Step 3: Surgery versus radiotherapy
Topic Reasons for surgery Reasons for radiotherapy
Treatment procedure I find it important that all 
cancer cells are removed from 
my body
I find it important that the 
cancer cells die and not 
grow further
Treatment side-effects I find bowel problems worse 
than incontinence
I find incontinence worse 
than bowel problems
Secondary treatment I am comforted by the thought 
that I can have radiation if 
surgery is unsuccessful
I accept that surgery is 
difficult after radiation
Fear for surgery I am not anxious about surgery I am anxious about surgery
DA: decision aid.
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randomized controlled trial (RCT) is in progress to evaluate the efficacy of this DA and to test 
whether decision outcomes align with patients’ preferences and values.36
Literature reports mixed findings from using VCEs in DAs and provide no clear guidelines for 
VCE design.25,26,28,37,38 However, there are indications to assume that the benefit of VCEs emerge 
after the decision is made and that VCE design should at least incorporate trade-offs between treat-
ment attributes.19,29 In the absence of design guidelines, further development of the VCE within the 
current DA was based on consensus within the development team. However, future research should 
look into the effectiveness of the VCE features used in this DA.
A specific aspect that needs to be investigated further is the labeling of VCE outcomes. For the 
current DA, the development team decided to label VCE outcomes with corresponding treatments. 
With a strong initial treatment preference (pre-DA), it could be that labeling may lead to patients 
seeking confirmation of their initial preference rather than achieving actual preference elicitation 
or misinterpreting information.39 However, for clarity reasons, we believed that the VCEs should 
have labeled outcomes to make patients aware of the consequence of their preference (e.g. when 
valuing incontinence worse than bowel problems, a patient should place radiation therapy over 
surgery on this topic). With this insight, the responses to the VCE contribute to the construction 
of an informed treatment preference. We expect that labeled VCEs support this process better 
Figure 1. Screen from DA step 3: information about active treatments.
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compared to unlabeled items. To gain more understanding on the development and usage of VCEs, 
more studies are needed to investigate VCE effectiveness and optimal presentation formats.
A potential limitation of the current development and usability test was the relatively small 
sample used in usability testing (N = 11). However, our sample included all relevant user groups: 
patients, urologists, nurses and a radiotherapist. All participants in usability testing consented on 
the usability and acceptability of the DA to a point where it seemed saturation was reached, and it 
Figure 2. DA summary page.
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Table 3. DA usability test summary.
Category Number of 
comments
Key findings Representative quotes Implications
Usability 41 Usage of the DA 
was intuitive and 
easy
Hardly needed any 
instructions
Navigated smoothly, 
without extra instructions
User-friendly
No need for changes to 
improve usability
Layout 26 The layout 
was clear and 
supportive 
of making 
comparisons and 
trade-offs
Layout is clear
Structured
The differences are 
presented next to each 
other that helps in the 
trade-off
No need to change the DA 
layout
Language 17 Used language is 
suitable for target 
group
Clear language
Comprehensive language
No need to change the writing 
style
Content 35 Content is 
complete and 
balanced
All pros and cons per 
option are named clearly
Good explanations
The general content was 
approved, but some aspects 
need adjustments
 12 Some risk 
information 
is difficult to 
understand
Are these numbers correct?
What does this figure 
mean?
What does the difference in 
color mean in the figures?
Descriptive notes and legends 
should be added to illustrations 
and risk figures
 30 Some details of 
the radiotherapy 
procedure needs 
adjustment or 
further elaboration
Brachytherapy also involves 
a surgical aspect
External beam radiotherapy 
affects the entire prostate, 
not solely the tumor
Radiation therapy content 
should be refined
Amount 16 Presented 
information is 
complete but can 
be redundant if all 
sections are read
Very complete
Still very information dense
Repetition in some texts
Patients should be allowed 
to skip parts that are not 
relevant to them, the message 
indicating this should be more 
prominent. The amount of 
information is needed to 
enable an informed decision.
Values 
clarification
15 Exercises are 
understood and 
used correctly
Statements help to weigh 
options
 
Summary 20 The summary is not 
clearly recognized 
as a summary and 
natural ending of 
the DA
Is this the end of the DA?
What does it mean that 
I have read 4 out of 4 
themes?
Some representation of 
personal situation would 
be nice
Summary was not recognized 
as being the end of the DA. 
Headings should more clearly 
indicate that a summary 
is presented. The clinical 
information entered at DA 
start (PSA, Gleason, eligible 
treatments) should also be 
displayed in the summary
Total 212  
DA: decision aid; PSA: prostate-specific antigen.
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Table 4. IPDASi v3 checklist.
Dimension Item Result
Information 1.  The decision support technology (DST) describes the health condition 
or problem (intervention, procedure or investigation) for which the 
index decision is required
✓
2.  The DST describes the decision that needs to be considered (the 
index decision)
✓
3.  The DST describes the options available for the index decision ✓
4.  The DST describes the natural course of the health condition or 
problem, if no action is taken.
✓
5.  The DST describes the positive features (benefits or advantages) of 
each option
✓
6.  The decision aid describes negative features (harms, side effects or 
disadvantages) of each option.
✓
7.  The DST makes it possible to compare the positive and negative 
features of the available options.
✓
8.  The DST shows the negative and positive features of options with 
equal detail (for example, using similar fonts, order and display of 
statistical information).
✓
Probabilities 1.  The DST provides information about outcome probabilities associated 
with the options (i.e. the likely consequences of decisions)
✓
2.  The DST specifies the defined group (reference class) of patients for 
which the outcome probabilities apply.
✓
3.  The DST specifies the event rates for the outcome probabilities (in 
natural frequencies).
✓
4.  The DST specifies the time period over which the outcome 
probabilities apply.
✓
5.  The DST allows the user to compare outcome probabilities across 
options using the same denominator and time period.
✓
6.  The DST provides information about the levels of uncertainty around 
event or outcome probabilities (e.g. by giving a range or by using 
phrases such as “our best estimate is …”).
✓
7.  The DST provides more than one way of viewing the probabilities 
(e.g. words, numbers and diagrams).
✓
8.  The DST provides balanced information about event or outcome 
probabilities to limit framing biases.
✓
Values 1.  The DST describes the features of options to help patients imagine 
what it is like to experience the physical effects.
✓
2.  The DST describes the features of options to help patients imagine 
what it is like to experience the psychological effects.
✓
3.  The decision support technology describes the features of options to 
help patients imagine what it is like to experience the social effects.
✓
4.  The decision support technology asks patients to think about which 
positive and negative features of the options matter most to them.
✓
Decision 
Guidance
1.  The decision support technology provides a step-by-step way to make 
a decision.
✓
2.  The decision support technology includes tools like worksheets or 
lists of questions to use when discussing options with a practitioner.
✓
 (Continued)
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was not expected additional participants would have resulted in new insights. The point of satura-
tion in qualitative research is often reached within 6–12 participants.40
Conclusion
The newly developed Dutch Pca treatment DA was evaluated positively by patients and care pro-
viders, both groups would recommend DA usage to others. Patients consented on easy usability 
and care providers confirmed the accuracy of the provided information. Adapting an existing tool 
to a (culturally) different setting and adjusting it to local circumstances seems a useful alternative 
to an entirely new development process. This could free resources to focus on other important 
aspects like DA implementation.
Dimension Item Result
Development 1.  The development process included finding out what clients or patients 
need to prepare them to discuss a specific decision.
✓
2.  The development process included finding out what health 
professionals need to prepare them to discuss a specific decision with 
patients.
✓
3.  The development process included expert review by clients/patients 
not involved in producing the decision support technology.
✓
4.  The development process included expert review by health 
professionals not involved in producing the decision aid.
✓
5.  The decision support technology was field tested with patients who 
were facing the decision.
✓
6.  The decision support technology was field tested with practitioners 
who counsel patients who face the decision.
✓
Evidence 1.  The decision support technology (or associated documentation) 
provides citations to the studies selected.
✓
2.  The decision support technology (or associated documentation) 
describes how research evidence was selected or synthesized.
✓
3.  The decision support technology (or associated documentation) 
provides a production or publication date.
✓
4.  The decision support technology (or associated documentation) 
provides information about the proposed update policy.
✓
5.  The decision support technology (or associated documentation) 
describes the quality of the research evidence used.
✓
Disclosure and 
Transparency
1.  The decision support technology (or associated technical 
documentation) provides information about the funding used for 
development.
✓
2.  The decision support technology includes author/developer 
credentials or qualifications.
✓
Plain Language 1.  The decision support technology (or associated documentation) 
reports readability levels (using one or more of the available scales).
✓
DST Evaluation 1.  There is evidence that the DST improves the match between the 
features that matter most to the informed patient and the option that 
is chosen.
✓
2.  There is evidence that the patient decision support technology helps 
patients improve their knowledge about options’ features.
✓
DST: decision support technology.
Table 4. (Continued)
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Practice implications
The process of developing and testing the DA as described in this article could be applied to the 
(cultural) adaptation of other pre-existing tools to different languages and clinical settings. As it 
enhances focus on usability and fit with clinical practice, it could be a fruitful step to improve 
implementation of DAs in routine clinical care.
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